Chemours (CC) Receiving Somewhat Favorable Press Coverage, Report Finds
Media coverage about Chemours (NYSE:CC) has trended somewhat positive on Tuesday, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Chemours earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news coverage about the specialty chemicals company an impact score of 45.0197606482358 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Chemours (NYSE CC) traded down $0.59 during trading hours on Tuesday, hitting $50.30. The company had a trading volume of 2,001,494 shares, compared to its average volume of 2,530,000. The company has a debt-to-equity ratio of 5.07, a current ratio of 2.19 and a quick ratio of 1.63. Chemours has a 12-month low of $21.22 and a 12-month high of $58.08. The stock has a market capitalization of $9,300.00 and a PE ratio of 34.69.
Chemours (NYSE:CC) last released its earnings results on Thursday, November 2nd. The specialty chemicals company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.11. The firm had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.59 billion. Chemours had a return on equity of 116.80% and a net margin of 4.86%. The firm’s revenue was up 13.3% on a year-over-year basis. During the same quarter last year, the business posted $0.61 earnings per share. research analysts predict that Chemours will post 3.65 EPS for the current year.
Chemours declared that its board has authorized a stock repurchase plan on Friday, December 1st that permits the company to buyback $500.00 million in shares. This buyback authorization permits the specialty chemicals company to buy shares of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board of directors believes its stock is undervalued.
Several analysts recently issued reports on the company. Barclays reiterated a “buy” rating and set a $60.00 target price on shares of Chemours in a research report on Wednesday, December 6th. Zacks Investment Research cut Chemours from a “buy” rating to a “hold” rating in a research report on Wednesday, December 6th. Goldman Sachs Group cut Chemours from a “buy” rating to a “neutral” rating and set a $55.00 target price for the company. in a research report on Wednesday, December 6th. UBS Group increased their target price on Chemours from $50.00 to $59.00 and gave the stock a “neutral” rating in a research report on Friday, November 3rd. Finally, Jefferies Group increased their target price on Chemours to $66.00 and gave the stock a “buy” rating in a research report on Monday, December 4th. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $57.89.
In other Chemours news, insider E Bryan Snell sold 11,878 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $53.25, for a total transaction of $632,503.50. Following the completion of the transaction, the insider now owns 63,063 shares in the company, valued at approximately $3,358,104.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Christian W. Siemer sold 15,088 shares of the firm’s stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $47.37, for a total value of $714,718.56. The disclosure for this sale can be found here. Insiders have sold a total of 32,874 shares of company stock valued at $1,678,129 in the last 90 days. 1.14% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Chemours (CC) Receiving Somewhat Favorable Press Coverage, Report Finds” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2018/01/09/chemours-cc-receiving-somewhat-favorable-press-coverage-report-finds.html.
Chemours Company Profile
The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.
Receive News & Stock Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related stocks with our FREE daily email newsletter.